<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7040080/results/search/disease/results.xml">
  <result pre="Influenza Virus by Inhibiting the Cap-Binding and Endonuclease Activity of" exact="Viral" post="RNA Polymerase HuAo12LiJing1TangWei1LiuGe12ZhangHaiwei1LiuChunlan1ChenXulin123*[], 1State Key Laboratory of Virology, Wuhan"/>
  <result pre="RNAs produced by the host RNA polymerase II (RNAPII). The" exact="viral" post="polymerases process the capped RNAs to produce short capped"/>
  <result pre="(RNAPII). The viral polymerases process the capped RNAs to produce" exact="short" post="capped RNA fragments that are used as primers to"/>
  <result pre="that are used as primers to initiate the transcription of" exact="viral" post="mRNAs. This process, known as cap-snatching, can be targeted"/>
  <result pre="was identified as an inhibitor against influenza a virus (IAV)" exact="infection" post="by targeting the cap-snatching activity of the viral polymerase."/>
  <result pre="virus (IAV) infection by targeting the cap-snatching activity of the" exact="viral" post="polymerase. Anthralin, an FDA-approved drug used in the treatment"/>
  <result pre="in the treatment of psoriasis, shows antiviral activity against IAV" exact="infection" post="in vitro and in vivo. Importantly, anthralin significantly reduces"/>
  <result pre="reduces weight loss, lung injury, and mortality caused by IAV" exact="infection" post="in mice. The mechanism of action study revealed that"/>
  <result pre="PB2 subunit and endonuclease activity of PA. As a result," exact="viral" post="mRNA transcription is blocked, leading to the decreases in"/>
  <result pre="viral mRNA transcription is blocked, leading to the decreases in" exact="viral" post="RNA replication and viral protein expression. In conclusion, anthralin"/>
  <result pre="blocked, leading to the decreases in viral RNA replication and" exact="viral" post="protein expression. In conclusion, anthralin has been demonstrated to"/>
  <result pre="to have the potential of an alternative antiviral against influenza" exact="virus infection." post="Also, targeting the captive pocket structure that includes the"/>
  <result pre="are enveloped viruses of the family Orthomyxoviridae that cause contagious" exact="respiratory" post="diseases and substantial morbidity and mortality (Palese, 2007). Since"/>
  <result pre="of M2 proteins that are ion channels, thereby preventing the" exact="viral" post="genomic fragments from entering the cytoplasm (Pinto and Lamb,"/>
  <result pre="as a purine analog, inhibits multiple RNA viruses by targeting" exact="viral" post="polymerase. But it increases uric acid, causes digestive system"/>
  <result pre="et al., 2013; Furuta et al., 2017). Compared with NAI," exact="viral" post="RNA polymerase inhibitors have higher tolerance and longer treatment"/>
  <result pre="and the elderly, which cannot shorten the course of the" exact="disease" post="(Hayden et al., 2018; Kakuya et al., 2019). The"/>
  <result pre="the variant virus with I38T/M/F replacement in PA decreased the" exact="susceptibility to" post="baloxavir, sometimes related to the rebound of virus titer"/>
  <result pre="been reported (Kanai et al., 2019). Nevertheless, the synthesis of" exact="viral" post="mRNA, cRNA, and vRNA is the central event and"/>
  <result pre="are attractive targets for small molecule inhibitors. In fact, the" exact="viral" post="polymerase of influenza virus is the target for several"/>
  <result pre="tree. This medication is used for the treatment of long-term" exact="psoriasis" post="by decreasing the number of DNA-synthesizing cells in the"/>
  <result pre="of the virus life cycle, which includes the transcription of" exact="viral" post="mRNAs and the replication of viral RNAs. To further"/>
  <result pre="includes the transcription of viral mRNAs and the replication of" exact="viral" post="RNAs. To further define the targets of anthralin, we"/>
  <result pre="define the targets of anthralin, we investigated the functions of" exact="viral" post="and host factors associated with virus RNA transcription and"/>
  <result pre="of Virology, Chinese Academy of Sciences, China. The Madin–Darby Canine" exact="Kidney" post="(MDCK) cells (ATCC CCL-34) and HEK293T cells were cultured"/>
  <result pre="in Dulbecco’s modified Eagle’s medium (DMEM; Gibco, Invitrogen). The Human" exact="Pulmonary" post="Epithelial (A549) cells (ATCC CCL-185) were maintained in Roswell"/>
  <result pre="1-step CHO High-Yield IVT Trial Kit acellular expression system (Thermo" exact="Fisher" post="Scientific). Open reading frames encoding PA, PB1, and PB2"/>
  <result pre="anti-NP antibodies were purchased from GeneTex Inc. (GeneTex, United States)." exact="Mouse" post="monoclonal antibodies against influenza A virus HA and M2"/>
  <result pre="from Active Motif company. Cytotoxicity and Antiviral Assays Madin–Darby Canine" exact="Kidney" post="or A549 cells were seeded in 96-well plates and"/>
  <result pre="After incubation at 37°C for 48 h, the inhibition of" exact="viral" post="replication was measured by the modified neuraminidase activity (NA)"/>
  <result pre="as the 50% effective (inhibitory) concentrations (EC50). For detection of" exact="infectious" post="virus yield reduction, the supernatants harvested 48 hpi were"/>
  <result pre="μM of anthralin at room temperature for 1 h, before" exact="infection" post="with PR8 virus at MOI of 0.01 at 4°C"/>
  <result pre="cell supernatants were harvested for detection of the production of" exact="infectious" post="virus particles by reinfection. For determining the stage of"/>
  <result pre="cells were precooled at 4°C for 30 min, followed by" exact="infection" post="with PR8 virus at 4°C for 1 h. Then"/>
  <result pre="were harvested 10 hpi for detection of the production of" exact="infectious" post="virus particles by reinfection. Indirect Immunofluorescence Assay MDCK and"/>
  <result pre="and 10% FBS) for 1 h and incubated with a" exact="primary" post="antibody against the NP for 1 h. The cells"/>
  <result pre="then washed with PBS and incubated with FITC-conjugated rabbit anti-mouse" exact="secondary" post="antibody (1:1000). The stained samples were then examined with"/>
  <result pre="stained samples were then examined with a Nikon’s Eclipse Ti" exact="inverted" post="microscope (Nikon, Tokyo, Japan). Western Blotting A549 cells were"/>
  <result pre="MOI of 5 for 1 h at 4°C for synchronizing" exact="viral" post="infections. After washing with cold PBS, the cells treated"/>
  <result pre="anthralin, and then harvested at the indicated times after infection." exact="Total" post="cells were lysed in radio-immunoprecipitation assay (RIPA) buffer and"/>
  <result pre="transferred to polyvinylidene difluoride membranes. After membranes were incubated with" exact="primary" post="antibody at 1:2000 dilution at 4°C for overnight, the"/>
  <result pre="antibody at 1:2000 dilution at 4°C for overnight, the appropriate" exact="secondary" post="antibody at 1:10000 dilution was added and incubated. The"/>
  <result pre="cell, and GAPDH. Fluorescence Microscopy and Image Analysis In time-course" exact="infection" post="experiments, cells grown on glass-bottom dishes (Cellvis formerly In"/>
  <result pre="In time-course infection experiments, cells grown on glass-bottom dishes (Cellvis" exact="formerly" post="In vitro Scientific, Mountain View, CA, United States) were"/>
  <result pre="room temperature. Cells were incubated with rabbit anti-PA, anti-PB1, anti-PB2" exact="primary" post="antibody overnight and then incubated with the Alexa Fluor"/>
  <result pre="anti-mouse IgG for 1 h. After washing, confocal images were" exact="acquired" post="with a 60 × objective, using a Nikon A1"/>
  <result pre="confocal microscope with random sampling. Quantitative RT-PCR of Virus RNAs" exact="Total" post="RNA and mRNA were extracted from cells using TRIzol"/>
  <result pre="5′-GTCGAAACGTACGTTCTCTCTATC-3′ for M2 vRNA, 5′-AGTAGAAACAAGGTAGTTTTTTACTC-3′ for M2 cRNA, oligo(dT)20 for" exact="viral" post="mRNA, and 5′-GGTGTGTTACAAAGGGC AGGG-3′ for 18S rRNA. Single-stranded cDNAs"/>
  <result pre="1-step CHO High-Yield IVT Trial Kit acellular expression system (Thermo" exact="Fisher" post="Scientific) according to the manufacturer’s protocols. The plasmids expressing"/>
  <result pre="of the bronchoalveolar lavage fluids (BALFs) were then harvested for" exact="viral" post="titer determination using the endpoint dilution assay in MDCK"/>
  <result pre="tested further the effect of anthralin in the production of" exact="infectious" post="influenza viruses in MDCK and A549 cells. The results"/>
  <result pre="(B) The antiviral effects of anthralin on the production of" exact="infectious" post="virions on two cell lines. The supernatants were harvested"/>
  <result pre="Virus titers in BALFs taken on the third day after" exact="infection" post="were measured by TCID50 assay determined on MDCK cells."/>
  <result pre="by hematoxylin and eosin staining. The results showed that the" exact="pulmonary" post="parenchyma and interstitial inflammatory infiltrations of the mice with"/>
  <result pre="of the lungs and protect mice against lethal influenza A" exact="virus infection." post="Taken together, we confirmed that anthralin inhibits influenza virus"/>
  <result pre="cells were washed twice with PBS and cultured in the" exact="absence of" post="anthralin. The influenza virus replication was found not affected"/>
  <result pre="the nucleus import of NP is not affected. Treatment after" exact="virus infection" post="by anthralin for 9 h eliminated the expression of"/>
  <result pre="nucleus import of NP is not affected. Treatment after virus" exact="infection" post="by anthralin for 9 h eliminated the expression of"/>
  <result pre="and localization of virus NP and HA in the synchronized" exact="infection" post="of A549 cells with anthralin treatment during different time"/>
  <result pre="that the anthralin treatment during 0–3 h after the initial" exact="infection" post="does not affect the internalization of influenza viruses. The"/>
  <result pre="of RNP into the nucleus, but seems to affect the" exact="viral" post="RNA replication or translation of viral proteins. The anthralin"/>
  <result pre="seems to affect the viral RNA replication or translation of" exact="viral" post="proteins. The anthralin treatment during 6–9 hpi suppressed less"/>
  <result pre="cycle of IAV, which includes the assembly and release of" exact="viral" post="particles. In summary, our results suggest that anthralin inhibits"/>
  <result pre="and vRNAs are synthesized and are assembled with newly translated" exact="viral" post="proteins to form viral RNP, which is stable without"/>
  <result pre="and are assembled with newly translated viral proteins to form" exact="viral" post="RNP, which is stable without being degraded (Te Velthuis"/>
  <result pre="newly translated viral proteins to form viral RNP, which is" exact="stable" post="without being degraded (Te Velthuis and Fodor, 2016). Finally,"/>
  <result pre="Fodor, 2016). Finally, the viruses are assembled and released to" exact="complete" post="the whole life cycle of IAVs (Pflug et al.,"/>
  <result pre="whether anthralin inhibits the down-stream event of the mid-stage of" exact="viral" post="lifecycle, we checked the translation of virus proteins using"/>
  <result pre="harvested at 3, 5, and 7 hpi for detection of" exact="viral" post="proteins. As shown in Figure 3B, at 3 hpi,"/>
  <result pre="were from the infected virions. However, at 5 hpi, the" exact="viral" post="proteins of PB1, PB2, PA, and NP were all"/>
  <result pre="were significantly reduced upon anthralin treatment. At 7 hpi, all" exact="viral" post="proteins accumulated to high levels in the untreated cells,"/>
  <result pre="was from the originally infected virions. The reason that other" exact="viral" post="proteins were not detected may contribute to the lower"/>
  <result pre="other viral proteins were not detected may contribute to the" exact="lower" post="efficiency of antibodies of other viral proteins. However, the"/>
  <result pre="may contribute to the lower efficiency of antibodies of other" exact="viral" post="proteins. However, the host protein GAPDH was not affected"/>
  <result pre="all the time, suggesting that the anthralin mediated reduction in" exact="viral" post="protein levels is not due to cytotoxic effect. Instead,"/>
  <result pre="due to cytotoxic effect. Instead, anthralin reduced the levels of" exact="viral" post="protein. FIGURE 3 Anthralin inhibits the transcription of the"/>
  <result pre="were infected with PR8 at an MOI of 5 and" exact="viral" post="protein levels were determined by western blotting of the"/>
  <result pre="of 5 and incubated for 3, 5, and 7 h." exact="Total" post="RNAs were prepared from cells, and quantitative RT-PCRs were"/>
  <result pre="or untreated A549 cells were immobilized 8 h after infection." exact="Viral" post="particles inside and outside of the cells were observed"/>
  <result pre="event of translation, which may contribute to the reduction of" exact="viral" post="protein levels, we investigated the effects of anthralin in"/>
  <result pre="we investigated the effects of anthralin in the synthesis of" exact="viral" post="mRNAs, cRNAs, and vRNAs of the gene segments 3,"/>
  <result pre="protein expression, we speculate that the assembly and release of" exact="infectious" post="virions can be blocked as well. To test our"/>
  <result pre="Taken together, we assume that anthralin inhibits the activity of" exact="viral" post="polymerase and reduces the levels of viral RNA replication"/>
  <result pre="the activity of viral polymerase and reduces the levels of" exact="viral" post="RNA replication and the viral protein expression, resulting in"/>
  <result pre="and reduces the levels of viral RNA replication and the" exact="viral" post="protein expression, resulting in a reduction in the production"/>
  <result pre="the influenza virus is a primer-dependent process that synthesizes the" exact="viral" post="mRNAs with a 5′-cap, but the polymerase of IAV"/>
  <result pre="et al., 1981). Therefore, we speculated that anthralin might affect" exact="viral" post="transcription by inhibiting the transcriptional competence of RNAPII. The"/>
  <result pre="transcription. When the cell is infected with the IAV, the" exact="viral" post="RdRp complexes complete RNA replication cycle by snatching the"/>
  <result pre="cell is infected with the IAV, the viral RdRp complexes" exact="complete" post="RNA replication cycle by snatching the caps produced by"/>
  <result pre="caps produced by host RNA II. (B) The expression of" exact="total" post="RNAPII, serine 2 phosphorylated and serine 5 phosphorylated RNAPII,"/>
  <result pre="of pPOLI-Fluc (Figure 4C). In the process of cap-snatching, the" exact="viral" post="polymerase PB2 captures the 5′-cap of nascent host capped"/>
  <result pre="fragments are then used as primers to initiate transcription of" exact="viral" post="mRNAs. Next, the co-localization of influenza virus polymerase complexes"/>
  <result pre="shown in Figure 4D, at 3 hpi, the host RNAPII" exact="localized" post="predominantly in the nucleus, while virus polymerase localized mostly"/>
  <result pre="host RNAPII localized predominantly in the nucleus, while virus polymerase" exact="localized" post="mostly in the cytoplasm. There is a very limited"/>
  <result pre="polymerase localized mostly in the cytoplasm. There is a very" exact="limited" post="co-localization that may be non-specific random co-localization. During 5–7"/>
  <result pre="RNA polymerase, instead, it may block directly the function of" exact="viral" post="RdRp. Anthralin Inhibits the Cap-Snatching Activity of Viral RdRp"/>
  <result pre="function of viral RdRp. Anthralin Inhibits the Cap-Snatching Activity of" exact="Viral" post="RdRp Since virus transcription relies on the binding of"/>
  <result pre="specifically the binding of capped RNA, but not vRNA with" exact="viral" post="RdRp (Figures 5A,B). Next, we detected the effects of"/>
  <result pre="vRNA by inhibiting the cap-binding and endonuclease activities of the" exact="viral" post="polymerase and does not directly interfere with the transcription"/>
  <result pre="vRdRp inhibitors. FIGURE 5 Anthralin inhibits the cap-snatching activity of" exact="viral" post="RdRp. (A) Binding of vRNA to vRdRp. The polymerase"/>
  <result pre="5′-FAM were added, and then incubated in the presence or" exact="absence of" post="anthralin for 30 min at 37°C. The complexes were"/>
  <result pre="is used topically in the management of psoriasis, dermatoses, and" exact="alopecia" post="areata. Anthralin is also used in biomedical research due"/>
  <result pre="long-term anthralin toxicity related either to skin exposure or to" exact="systemic" post="issues. In this study, we demonstrated that anthralin inhibits"/>
  <result pre="replication of cRNA and vRNA but not the transcription of" exact="viral" post="RNA that have been detected 7 hpi (Figure 3C)."/>
  <result pre="been detected 7 hpi (Figure 3C). While the synthesis of" exact="viral" post="mRNA, cRNA, and vRNA are all inhibited by anthralin"/>
  <result pre="on the effect of anthralin on the transcription functions of" exact="viral" post="RdRp. The influenza virus RdRp cannot synthesize the capped"/>
  <result pre="we studied the effects of anthralin on the functions of" exact="viral" post="RdRp. The influenza virus RdRp is composed of the"/>
  <result pre="They are responsible for interacting with the terminal ends of" exact="viral" post="promoters and for catalyzing the nucleotidyl transfer reaction. The"/>
  <result pre="3- base pair interactions with the 3′ terminus of the" exact="viral" post="genome segment, depending on the sequence of the primer"/>
  <result pre="The use of small molecules to affect multiple functions of" exact="viral" post="polymerase is beneficial to the development of new antiviral"/>
  <result pre="through a chemical modification to improve its efficacy and to" exact="lower" post="its toxicity, and provide a new strategy for the"/>
  <result pre="virus polymerase that associated with multiple functions in cap-snatch during" exact="viral" post="RNA transcription. Data Availability Statement All datasets generated for"/>
  <result pre="The authors declare that the research was conducted in the" exact="absence of" post="any commercial or financial relationships that could be construed"/>
  <result pre="10.1016/j.molcel.2017.04.01628506463 FurutaY.KomenoT.NakamuraT. (2017). Favipiravir (T-705), a broad spectrum inhibitor of" exact="viral" post="RNA polymerase.Proc. Jpn. Acad. Ser. B Phys. Biol. Sci.93449–463."/>
  <result pre="baloxavir marboxil against influenza in children.Pediatr. Int.61616–618. 10.1111/ped.1385531195429 KanaiN.HashimotoT.FukudaM.ShijyoT. (2019)." exact="Acute" post="ischemic colitis with hematochezia related to baloxavir marboxil treatment"/>
  <result pre="marboxil against influenza in children.Pediatr. Int.61616–618. 10.1111/ped.1385531195429 KanaiN.HashimotoT.FukudaM.ShijyoT. (2019). Acute" exact="ischemic colitis" post="with hematochezia related to baloxavir marboxil treatment for influenza"/>
  <result pre="against influenza in children.Pediatr. Int.61616–618. 10.1111/ped.1385531195429 KanaiN.HashimotoT.FukudaM.ShijyoT. (2019). Acute ischemic" exact="colitis" post="with hematochezia related to baloxavir marboxil treatment for influenza"/>
  <result pre="repertoire of H1N1 influenza provides insight into the mechanism of" exact="viral" post="transcription initiation.Nucleic Acids Res.435052–5064. 10.1093/nar/gkv33325901029 KrammerF.SmithG. J. D.FouchierR. A."/>
  <result pre="McKimm-BreschkinJ. L.JiangS.HuiD. S.BeigelJ. H.GovorkovaE. A.LeeN. (2018). Prevention and treatment of" exact="respiratory" post="viral infections: presentations on antivirals, traditional therapies and host-directed"/>
  <result pre="L.JiangS.HuiD. S.BeigelJ. H.GovorkovaE. A.LeeN. (2018). Prevention and treatment of respiratory" exact="viral" post="infections: presentations on antivirals, traditional therapies and host-directed interventions"/>
  <result pre="PflugA.GuilligayD.ReichS.CusackS. (2014). Structure of influenza A polymerase bound to the" exact="viral" post="RNA promoter.Nature516355–360. 10.1038/nature1400825409142 PintoL. H.LambR. A. (2007). Controlling influenza"/>
  <result pre="(2016). Influenza virus RNA polymerase: insights into the mechanisms of" exact="viral" post="RNA synthesis.Nat. Rev. Microbiol.14479–493. 10.1038/nrmicro.2016.8727396566 Te VelthuisA. J. W."/>
  <result pre="rna-polymerase to sequences located at the 5’ ends of the" exact="viral" post="RNAs.J. Virol.685108–5116. 10.1128/jvi.68.8.5108-5116.19948035510 ZaborowskaJ.EgloffS.MurphyS. (2016). The pol II CTD:"/>
 </snippets>
</snippetsTree>
